Manremyc, a CataloniaBio & HealthTech member that has developed a tuberculosis probiotic, has opened a crowdfunding round to raise €250,000 through Capital Cell. So far, the company has raised 37% of its goal, including investment from the Reig family (main shareholder of the pharmaceutical corporation Reig Jofre).
Manremyc is a spin-off of the Institute for Health Science Research Germans Trias i Pujol (IGTP). The technology prevents people from contracting tuberculosis using a natural product, administered orally that is suitable for regions with high incidence rates and limited resources. This is why the company has been B Corp certified since 2016.
The biotech firm has closed distribution deals in 65 countries. Dr Pere-Joan Cardona, co-founder and CEO of Manremyc, explains, “with the funds we’re raising, we want to consolidate our move into the market, beginning in September with Kenya and the Philippines.”
Tuberculosis continues to be the number one cause of death by disease in the world, ahead of malaria and AIDS.
Comments